The beliefs about allergic rhinitis and its treatment options from people in Central Thailand.

IF 1.6 Q3 ALLERGY
Asia Pacific Allergy Pub Date : 2022-01-26 eCollection Date: 2022-01-01 DOI:10.5415/apallergy.2022.12.e11
Sirada Patcharanarumol, Tanya Wachiruksasawakul, Watanyu Phadungvorasart, Orapan Poachanukoon
{"title":"The beliefs about allergic rhinitis and its treatment options from people in Central Thailand.","authors":"Sirada Patcharanarumol,&nbsp;Tanya Wachiruksasawakul,&nbsp;Watanyu Phadungvorasart,&nbsp;Orapan Poachanukoon","doi":"10.5415/apallergy.2022.12.e11","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis (AR) has substantially negative impacts on patients' quality of life. Besides conventional medicines, many patients use alternative approaches, which sometimes were misconception.</p><p><strong>Objective: </strong>This study aims to explore and compare the beliefs about AR and its treatment options between 2 different groups; control and AR patient groups.</p><p><strong>Methods: </strong>A cross-sectional study of 518 respondents residing in the central region of Thailand has been conducted using a self-reported questionnaire which consists of 3 parts; personal profile, the International Study of Asthma and Allergies in Childhood (ISAAC) questions, and the beliefs. ISAAC is applied for identifying respondents as the control or the AR group.</p><p><strong>Results: </strong>From a total of 518 respondents, 311 (60.0%) were identified as the AR group. The demographic data between the control and the AR group has no statistical difference (<i>p</i> > 0.05). Regarding the beliefs about AR characteristics, 56.1% of the AR group believe that low immunity causes AR while the number of the control group reaches 56%. Thirty-nine point two percent for the AR group and 38.6% for the control group believe that AR is a fatal disease. The belief that AR can be spread by droplet/airborne transmission is 22.8% and 28.5% for the AR and the control group, respectively. About AR treatment options, 60.1% of the AR group and 43% of the control group believe that taking vitamin C can relieve AR symptoms, which has a statistical difference (<i>p</i> < 0.05) between the 2 groups. The belief that prolonged use of antihistamine drugs can cause drug resistance is 29.9% and 24.6% for AR and control groups, respectively.</p><p><strong>Conclusion: </strong>Both groups of respondents mostly share common beliefs about AR characteristics and treatment options in which the AR group has higher percentage in some beliefs. Therefore, health literacy should be promoted in order to improve patient's care.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 1","pages":"e11"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/12/apa-12-e11.PMC8819421.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.2022.12.e11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Allergic rhinitis (AR) has substantially negative impacts on patients' quality of life. Besides conventional medicines, many patients use alternative approaches, which sometimes were misconception.

Objective: This study aims to explore and compare the beliefs about AR and its treatment options between 2 different groups; control and AR patient groups.

Methods: A cross-sectional study of 518 respondents residing in the central region of Thailand has been conducted using a self-reported questionnaire which consists of 3 parts; personal profile, the International Study of Asthma and Allergies in Childhood (ISAAC) questions, and the beliefs. ISAAC is applied for identifying respondents as the control or the AR group.

Results: From a total of 518 respondents, 311 (60.0%) were identified as the AR group. The demographic data between the control and the AR group has no statistical difference (p > 0.05). Regarding the beliefs about AR characteristics, 56.1% of the AR group believe that low immunity causes AR while the number of the control group reaches 56%. Thirty-nine point two percent for the AR group and 38.6% for the control group believe that AR is a fatal disease. The belief that AR can be spread by droplet/airborne transmission is 22.8% and 28.5% for the AR and the control group, respectively. About AR treatment options, 60.1% of the AR group and 43% of the control group believe that taking vitamin C can relieve AR symptoms, which has a statistical difference (p < 0.05) between the 2 groups. The belief that prolonged use of antihistamine drugs can cause drug resistance is 29.9% and 24.6% for AR and control groups, respectively.

Conclusion: Both groups of respondents mostly share common beliefs about AR characteristics and treatment options in which the AR group has higher percentage in some beliefs. Therefore, health literacy should be promoted in order to improve patient's care.

Abstract Image

Abstract Image

Abstract Image

泰国中部人们对过敏性鼻炎及其治疗方案的看法。
背景:变应性鼻炎(Allergic rhinitis, AR)对患者的生活质量有显著的负面影响。除常规药物外,许多患者使用替代方法,这有时被误解。目的:本研究旨在探讨和比较两组患者对AR及其治疗方案的认知;对照组和AR患者组。方法:对居住在泰国中部地区的518名受访者进行了横断面研究,采用自报告问卷,该问卷由3部分组成;个人简介,国际儿童哮喘和过敏研究(ISAAC)问题,以及信仰。ISAAC用于将应答者识别为控制组或AR组。结果:在总共518名受访者中,311名(60.0%)被确定为AR组。对照组与AR组人口学数据无统计学差异(p > 0.05)。在对AR特征的看法上,56.1%的AR组认为免疫力低下导致AR,而对照组的这一比例达到56%。认为AR是一种致命疾病的人分别为33.2%和38.6%。认为AR可通过飞沫/空气传播的比例在AR组和对照组分别为22.8%和28.5%。关于AR治疗方案,60.1%的AR组和43%的对照组认为服用维生素C可以缓解AR症状,两组比较差异有统计学意义(p < 0.05)。认为长期使用抗组胺药物会导致耐药的比例在AR组和对照组分别为29.9%和24.6%。结论:两组受访者对AR特征和治疗方案大多有共同的信念,其中AR组在某些信念中的比例更高。因此,应促进健康素养,以改善患者的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
5.90%
发文量
33
期刊介绍: Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信